The Technical Analyst
Opiant Pharmaceuticals [OPNT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Opiant Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $20.65
America/New_York / 1 mar 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 108.80 mill |
| EPS: | -6.53 |
| P/E: | -3.16 |
| Earnings Date: | Aug 03, 2022 |
| SharesOutstanding: | 5.27 mill |
| Avg Daily Volume: | 0.0724 mill |
| RATING 2023-03-02 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.16 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.54x |
| Company: PE -3.16 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 20.37 - 20.93 ( +/- 1.35%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-02 | Silver Gabrielle Alison | Sell | 21 343 | Common Stock |
| 2023-03-02 | Silver Gabrielle Alison | Sell | 2 500 | Stock Option (right to buy) |
| 2023-03-02 | Silver Gabrielle Alison | Sell | 2 000 | Common Stock |
| 2023-03-02 | Silver Gabrielle Alison | Sell | 2 500 | Common Stock |
| 2023-03-02 | Silver Gabrielle Alison | Sell | 2 500 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| -97.64 |
| Last 100 transactions |
| Buy: 31 334 | Sell: 1 708 118 |
Forecast:
01:40 - $23.89
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $20.65 (0.00% ) |
| Volume | 0.563 mill |
| Avg. Vol. | 0.0724 mill |
| % of Avg. Vol | 777.80 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OPNT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OPNT
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Latest Press Releases
2022-12-06 12:07:00 - Press Release
Shareholder Investigation: Halper Sadeh Llc Investigates Elvt, Opnt, Bnft, Abmd
New york , dec. 6, 2022 /prnewswire/ -- halper sadeh llc, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: elevate credit, inc. (nyse: elvt)'s sale to an affiliate of park cities asset management llc for $1.87 per share. if you are an elevate credit shareholder, click here to learn more about your rights and options.
2022-10-27 16:05:00 - Press Release
Opiant Pharmaceuticals To Report Third Quarter 2022 Financial Results And Host Conference Call And Webcast On November 14, 2022
Santa monica, calif., oct. 27, 2022 (globe newswire) -- opiant pharmaceuticals, inc. (“opiant” or “company”) (nasdaq: opnt), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended september 30, 2022, after the financial markets close on monday, november 14, 2022.
2022-08-01 16:05:00 - Press Release
Opiant Pharmaceuticals To Report Second Quarter 2022 Financial Results And Host Conference Call And Webcast On August 11, 2022
Santa monica, calif., aug. 01, 2022 (globe newswire) -- opiant pharmaceuticals, inc. (“opiant” or “company”) (nasdaq: opnt), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the second quarter ended june 30, 2022, after the financial markets close on thursday, august 11, 2022.
2022-05-03 08:00:00 - Press Release
Opiant Pharmaceuticals To Report First Quarter 2022 Financial Results And Host Conference Call And Webcast On May 10, 2022
Santa monica, calif., may 03, 2022 (globe newswire) -- opiant pharmaceuticals, inc. (“opiant”) (nasdaq: opnt), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended march 31, 2022, after the financial markets close on tuesday, may 10, 2022.
2022-03-07 16:05:00 - Press Release
Opiant Pharmaceuticals To Report Fourth Quarter 2021 Financial Results And Host Conference Call And Webcast On March 15, 2022
Santa monica, calif., march 07, 2022 (globe newswire) -- opiant pharmaceuticals, inc. (“opiant”) (nasdaq: opnt), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report fourth quarter 2021 financial results and pipeline updates on tuesday, march 15, 2022, after u.s. financial markets close.
Latest News
2023-02-11 03:50:01 - Seeking Alpha
What's The Opiant CVR Worth?
Opiant appears on track to be acquired for $20/share and offers various Contingent Value Rights (CVRs) linked to a potential drug launch. The drug helps with opioid reversal after an overdose and has a scheduled FDA review date of May 2023.
2023-01-13 14:26:12 - Seeking Alpha
Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In
I love to get a CVR during a takeover process. This happens a lot when pharma or biotech companies with important unapproved assets get bought.
2022-11-14 10:58:37 - InvestorPlace
Why Is Opiant Pharma (OPNT) Stock Up 116% Today?
Opiant Pharmaceuticals (NASDAQ: OPNT ) stock is rocketing higher on Monday following news that Indivior is acquiring the Narcan maker! Indivior is offering to acquire shares of OPNT stock for $28 each.
2022-10-27 16:05:00 - GlobeNewsWire
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.
2022-08-12 09:10:08 - Seeking Alpha
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2022 Results - Earnings Call Transcript
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Ben Atkins - VP Communications and Investor Relations Roger Crystal - President, Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Carl Byrnes - Northland Capital Markets Trevor Allred - Oppenheimer Operator Greetings, and welcome to Opiant Pharmaceuticals Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
2022-08-01 16:05:00 - GlobeNewsWire
Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
SANTA MONICA, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the second quarter ended June 30, 2022, after the financial markets close on Thursday, August 11, 2022.
2022-05-14 18:34:06 - Seeking Alpha
Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT ) Q1 2022 Results Conference Call May 10, 2022 4:30 PM ET Company Participants Ben Atkins - Vice President, Communications and Investor Relations Dr. Roger Crystal - Chief Executive Officer Dr. Phil Skolnick - Chief Scientific Officer David O'Toole - Chief Financial Officer Matt Ruth - Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Leland LelGershell - Oppenheimer David Bautz - Zacks Operator Greetings, and welcome to Opiant Pharmaceuticals First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
2022-05-03 08:00:00 - GlobeNewsWire
Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022
SANTA MONICA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended March 31, 2022, after the financial markets close on Tuesday, May 10, 2022.
2022-04-28 09:06:10 - Benzinga
Why Opiant Pharmaceuticals Shares Are Soaring Today
Opiant Pharmaceuticals Inc (NASDAQ: OPNT) announced topline results from a pharmacodynamic (PD) study for OPNT003, nasal nalmefene for opioid overdose. This crossover study conducted in healthy volunteers compared 3 mg nasal nalmefene hydrochloride with 4 mg nasal naloxone.
2022-03-15 19:00:02 - Seeking Alpha
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q4 2021 Results - Earnings Call Transcript
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q4 2021 Results - Earnings Call Transcript